Neupulse Launches Drug-Free Wearable Offering New Hope for People Living With Tourette Syndrome

Neurotechnology company Neupulse has announced a first-of-its-kind wearable device proven to dramatically reduce the frequency and urge of tics in people l...

December 17, 2025 | Wednesday | News
The CEO Playbook For Biopharma In An Age Of Regulatory And Market Volatility

Biopharmaceutical leaders today are charting a course through unprecedented regulatory uncertainty and market turbulence. From shifting FDA and EMA approva...

December 16, 2025 | Tuesday | Analysis
Tjoapack Announces Major U.S. Expansion with New 170,000-sq-ft Pharmaceutical Packaging Facility

Tjoapack, a leading global contract packaging organization, has announced a significant strategic investment to expand its operational footprint in the U.S...

December 10, 2025 | Wednesday | News
Pfizer Phase 3 BASIS Study Shows HYMPAVZI Delivers 93% Bleed Reduction in Hemophilia With Inhibitors

-Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolesc...

December 08, 2025 | Monday | News
Sarepta Receives FDA Approval to Initiate Cohort 8 Evaluating Sirolimus With ELEVIDYS in Non-Ambulant Duchenne

Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study, which is expected to be...

November 26, 2025 | Wednesday | News
MDA Applauds FDA Approval of Itvisma, the First Gene Replacement Therapy for a Broad SMA Population

The Muscular Dystrophy Association (MDA)  called the U.S. Food and Drug Administration’s approval of Itvisma (onasemnogene abeparvovec-brve), ...

November 26, 2025 | Wednesday | News
AGC Biologics Partners with AAVantgarde to Advance Dual-Vector AAV Gene Therapies for Inherited Blindness

Partnership accelerates AGC Biologics' leadership in the AAV market, applying its BravoAAV™ platform to complex gene therapies for inherited blin...

November 24, 2025 | Monday | News
Purdue Pharma Reports Positive Phase 1 Results for Tinostamustine in Difficult-to-Treat Glioblastoma

Data reveals positive preliminary results for investigational agent tinostamustine as a potential first-in-class treatment for glioblastoma. -...

November 20, 2025 | Thursday | Reports
Thermo Fisher Opens Flagship United States Center in Philadelphia to Accelerate Cell & Gene Therapy Development

  New state-of-the-art facility in Philadelphia provides integrated lab and collaboration space along with tailored guidance to help move advanced th...

November 19, 2025 | Wednesday | News
Emerging EMEA: A Vital and Evolving Landscape for Biopharma Strategy, Offering a Blueprint for Agile Market Access and Global Patient Reach

  In these diverse and dynamic markets, adaptation is not a strategy; it is a prerequisite for thriving. Success requires a fundamental shift in mind...

November 19, 2025 | Wednesday | Opinion
PrognomiQ Launches ProVue Lung, a Blood-Based Test Designed for Earlier Lung Cancer Detection

Initial commercial availability begins through an Early Experience Program with Penn Highlands Healthcare and Allegheny Health Network –  Pr...

November 19, 2025 | Wednesday | News
Johnson & Johnson to Acquire Halda in $3.05 Billion Deal to Expand First-in-Class RIPTAC™ Therapeutic Platform

Halda to be acquired by Johnson & Johnson for $3.05 billion in cash Halda recently presented positive Phase 1/2 data for HLD-0915 in metastatic ca...

November 18, 2025 | Tuesday | News
Parse Biosciences’ GigaLab to Power 5 Million–TCR Mapping Effort With Third Rock Ventures

Third Rock Ventures and Parse Biosciences  announced a strategic collaboration to create an unprecedented atlas of 5 million T cell receptors (TCRs)...

November 17, 2025 | Monday | News
Legend Biotech Expands U.S. R&D Footprint With New Philadelphia Innovation Center

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a U.S.-based global leader in cell therapy,  announced the official opening and ribbon c...

November 17, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close